Search PubMed⌕ Search

Biomedical subjects

Jie Jin

Publications and source records attributed to Jie Jin.

At least 19 recordsLinked to original sources

An ATP-Driven N Protein-DDX21 Molecular Switch Dynamically Controls SARS-CoV-2 RNA G-Quadruplex Heterogeneity.

The SARS-CoV-2 RNA genome functions as a highly structured regulatory scaffold. Although bioinformatic analyses predict widespread RNA G-quadruplexes (G4s) across the viral genome, their structural diversity and regulatory mechanisms remain poorly understood. Here, we report a diverse landscape of viral G4s encompassing parallel and non-canonical topologies with remarkable thermostability. Unlike typical eukaryotic G4s, these two-tetrad viral G4s exhibit a hierarchical ion-dependent mechanism, in which K+ establishes the core fold, and Mg2 + acts as a secondary regulator promoting conformational compaction. Single-molecule FRET analysis further distinguishes rigid, long-lived G4 folds from highly dynamic, metastable species, defining a continuum of conformational states along the viral genome. Functionally, we identify a synergistic yet competitive interplay between the viral nucleocapsid (N) protein and host helicase DDX21. While the N protein acts as a molecular chaperone to promote G4 folding, DDX21 selectively resolves these structures in an ATP-dependent manner. Strikingly, N and DDX21 jointly constitute a finely tuned, ATP-driven molecular switch, where ATP availability dictates the equilibrium between G4-stabilized and resolved states. Our findings establish a mechanistic framework for the active regulation of SARS-CoV-2 RNA architecture and reveal a multilayered host-virus regulatory axis that modulates viral genome heterogeneity.

DEAD‐box helicases↗

Age as a core disease modifier: Distinct clinical, molecular and prognostic landscapes of essential thrombocythaemia in adolescents and young adults.

Essential thrombocythaemia (ET) in adolescents and young adults (AYA, 15-39 years) is a distinct entity with an incompletely defined prognosis. In this multicentre retrospective study, 1728 ET patients from 29 centres across China were stratified into AYA (n = 328) and non-AYA (≥40 years, n = 1400) cohorts. We compared their clinical profiles, genomic landscapes, long-term outcomes and risk factors for progression to post-ET myelofibrosis (MF). AYA patients had fewer cardiovascular risks and lower thrombosis rates, but higher rates of extreme thrombocytosis. Molecularly, AYA patients were enriched for calreticulin (CALR) mutations, whereas Janus kinase 2 (JAK2) predominated in older patients. The burden of non-driver mutations (tet methylcytosine dioxygenase 2 [TET2], DNA methyltransferase 3A [DNMT3A], ASXL transcriptional regulator 1 [ASXL1], SH2‑B adaptor protein 3 [SH2B3]) was lower in AYA patients. Consequently, AYA patients achieved superior long-term outcomes across all key survival endpoints, including overall, myelofibrosis-free and leukaemia-free survival. Analysis of post-ET MF progression risks identified age-specific patterns: CALR mutations are enriched in younger patients and show an age-specific association with MF progression. AYA-ET constitutes a unique clinicomolecular subtype with a favourable prognosis, supporting age-stratified management. The enrichment of CALR mutations and their specific link to MF progression in young patients underscore the urgent need for targeted therapies against CALR-mutant clones.

adolescents and young adults (AYA)↗

The high incidence of varicella herpes zoster with the use of bortezomib in 10 patients.

Bortezomib, a proteasome inhibitor, has been used for patients with refractory and relapsed multiple myeloma, lymphoma and leukemia. We used bortezomib in ten refractory or relapsed patients (seven of multiple myeloma, two of lymphoma and one of acute myeloblastic leukemia). Six out of ten (60%) patients developed varicella herpes zoster after the complete of one cycle of bortezomib. The incidence of varicella herpes zoster was higher than reported in the literature. It may be due to immunosuppression caused by the combination of high-dose dexamethasone or other drugs. We considered that prophylactic antiviral medication could be used in predisposed patients to reduce the incidence of varicella herpes zoster.

Adult↗

Natural history of benign prostate hyperplasia.

BACKGROUND: Benign prostate hyperplasia is one of the most common diseases affecting the health of the aging males. Watchful waiting is an acceptable management strategy for benign prostate hyperplasia in which the patient is monitored by the physician but receives no active intervention. The epidemiological data on this are lacking in China. Our study was designed to evaluate the changes of signs and symptoms of patients with benign prostate hyperplasia during management by watchful waiting in China. METHODS: One hundred and forty-five patients with benign prostate hyperplasia aged > 50 years were enrolled in management by watchful waiting. All the patients were visited every 6 months and were given an International Prostate Symptom Score and Quality of Life questionnaire to complete. They also had uroflowmetry and were assessed using ultrasonography to get the volume of prostate, transition zone and amount of residual urine. The Student's t test, the Chi-square test, and variance analysis were used in the statistical analysis. RESULTS: All patients were visited after 6 months, the mean volume of transitional zone was found to have increased by 1.6 ml (P < 0.01), International Prostate Symptom Score was increased by 0.8 (P < 0.01) and Quality of Life was increased by 0.2 (P < 0.01), and there was no statistical change in other data. Among these patients, 17.9% (26/145) visited again after 12 months when the data failed to show a statistically significant difference among the three groups (0, 6, and 12 months). CONCLUSIONS: After one year's follow-up, the progression of benign prostate hyperplasia was slow and the clinical data did not undergo much change.

Aged↗

Aberrant methylation of the 8p22 tumor suppressor gene DLC1 in renal cell carcinoma.

Epigenetic mechanisms involving DNA methylation and chromatin remodeling are important in silencing tumor suppressor genes (TSG) in various malignancies, including renal cell carcinoma (RCC). DLC1 (deleted in liver cancer 1)/ARHGAP7 is a recently identified 8p22 candidate TSG. Frequent methylation of the DLC1 promoter with resultant gene silencing has been reported in several tumors, but not in RCC yet. We examined DLC1 promoter methylation in 34 primary RCCs and the corresponding non-malignant tissues, and the correlation of DLC1 methylation with the clinicopathological characteristics of RCC patients. Although DLC1 methylation and downregulation were only detected in one of seven RCC cell lines using methylation-specific PCR (MSP) and semi-quantitative reverse-transcription PCR, we found that the DLC1 promoter was methylated in 35% (12/34) of primary RCC tumors, which was further confirmed by direct sequencing of MSP products and high-resolution bisulfite genomic sequencing. In contrast, only one of the 34 (3%) non-malignant renal tissues had weak methylation. Aberrant DLC1 methylation appeared to be a relatively early event during renal tumorigenesis since 33% of the RCC tumors with pT1 (TNM staging) showed methylation, which is similar to other late stage tumors. Thus, our results demonstrated that DLC1 methylation occurs in a subset of RCC tumors and may play a role in renal carcinogenesis.

Adult↗

[Effects of Imatinib mesylate on the development of dendritic cells derived from bone marrow mononuclear cells of patients with chronic myeloid leukemia].

OBJECTIVE: To investigate the effects of Imatinib mesylate (STI571) on the development of dendritic cells (DC) derived from the bone marrow mononuclear cells of patients with chronic myeloid leukemia (CML). METHODS: Bone marrow mononuclear cells (BMMNC) from CML patients were cultured initially using multiple cytokine combinations as follows: recombined human granulocyte/macrophage colony-stimulating-factor (rhGM-CSF) plus recombined human interleukin-4 (rhIL-4) as control groups, rhGM-CSF plus rhIL-4 and STI571 as experimental groups, and from day 8 added recombined human tumor necrosis factor-alpha (rhTNF-alpha) for stimulating maturation. The morphologic features of cells were observed by Wright's staining, Cytogenetic analysis was performed by Fluorescence in-situ hybridization (FISH), phenotypes were assessed by flow cytometry, and the functions of antigen-presenting were assayed by mixed lymphocyte reaction (MLR). The concentration of VEGF was detected by enzyme-linked immunosorbent assay (ELISA). NF-kappaB activation was evaluated by TransAM(TM) ELISA kit. RESULTS: CML experimental groups treated with STI571 displayed features in morphology which were similar to those of control groups with delicate membrane projections. FISH confirmed the DC of both CML groups were leukemic origin. In comparison with the CML control groups, the CML experimental groups showed an increased expression of CD80, CD86, CD83 and HLA-DR and showed more intense abilities of allogeneic antigen presentation. The concentration of VEGF was dramatically reduced, and yet NF-kappaB activation was increased in experimental groups. CONCLUSION: STI571 could promote the activation/maturation of DC derived from BMMNCs of patients with CML in vitro, which might be partially responsible for the fact that the inhibitory effect of VEGF on DC NF-kappaB activation was relieved through STI571 inhibiting the overproduction of VEGF in CML.

Adult↗

Treatment with bortezomib in a patient with heavily pretreated refractory T-cell lymphoblastic lymphoma.

T-cell lymphoblastic lymphomas are highly aggressive non-Hodgkin's lymphoma (NHL) and account for approximately 3% of all adult NHL histologies, with poor prognosis. We describe a 38-year-old patient with T-cell lymphoblastic lymphoma, who responds to bortezomib and doxorubincin combination, following a failure of conventional chemotherapy. Two months after treatment, the patient showed near complete remission of the lymphadenopathy. These data suggest a possible synergistic effect with bortezomib in combination with doxorubincin and dexamethasone. To our knowledge, this is the first case of T-cell lymphoblastic lymphoma treated with bortezomib.

Adult↗

[Relationship between visceral adipose tissue and prevalence of metabolic syndrome MS in patients with MS, and hypertension and/or diabetes].

OBJECTIVE: To investigate the relationship between the visceral adipose (VA) accumulation and the prevalence of metabolic syndrome (MS) in patients with MS, and hypertension and/or diabetes. METHODS: VA area was measured by computed tomography (CT) in 564 patients with with MS, and hypertension and/or diabetes, 308 males and 256 females. Body mass index (BMI), waist circumference (WC) and waist-to-hip ratio (WHR) were assessed. Receiver operating characteristic (ROC) curve was used as index for analysis. RESULTS: (1) The VA of the patients with MS was 116 cm(2) +/- 38 cm(2), significantly higher than those of the patients with hypertension and diabetes (72 cm(2) +/- 34 cm(2) and 64 cm(2) +/- 34 cm(2) respectively, both P < 0.01). ROC curve analysis showed that the optimal cut-off points of VA for hypertriglyceridemia, hypo-high density lipoproteinemia, abdominal obesity and MS was 91 - 107 cm(2) for men; and 70 - 72 cm(2) for women. (2) The anthropometric parameters to the corresponding optimal cut-off points of VA were as follow: BMI, WC, and WHP were 25 kg/m(2), 89 cm, and 0.95 - 0.96 for men; and 24 - 25 kg/m(2), 82 - 84 cm, and 0.91 for women. Both the cut-off points of VA in assessing hyperglycemia and in assessing hypertension could not be found out. (3) The prevalence of MS was significantly increased when VA >or= 55 cm(2) in women and when VA >or= 70 cm(2) in men respectively. CONCLUSION: There is a gender difference in the accumulation of the VA tissue. Even in the subjects with overweight, abdominal obesity and dyesmetabolism have appeared in patients. The prevalence of MS is significantly increased with the intra-abdominal fat accumulation.

Adipose Tissue↗

Arsenic trioxide induces not only apoptosis but also autophagic cell death in leukemia cell lines via up-regulation of Beclin-1.

Although recent data shows that arsenic trioxide (As2O3) is capable of inducing cell death via cell cycle arrest and apoptosis both in acute promyelocytic leukemia (APL) and in non-APL cells, the mechanisms of As2O3-mediated cell death are not fully understood. In this study, we investigated the in vitro effects of As2O3 on cell growth inhibition and cell death in human T-lymphocytic leukemia and myelodysplastic syndrome (MDS) cell lines. As2O3 significantly inhibited the proliferation of Molt-4 and Mutz-1 cells in dose- and time-dependent manner. Autophagic cell death (programmed cell death type II) and apoptosis (programmed cell death type I) were activated together in leukemia cell lines after exposed to As2O3. Numerous large cytoplasmic inclusions and vacuoles were observed in As2O3-treated cells using electron microscope. Furthermore, 3-methyladenine (an autophagy inhibitor) significantly reduced autophagic cell death and sequentially induced apoptosis. Finally, leukemia cells treated with 4 microM As2O3 showed a considerable up-regulation of Beclin-1 (a Bcl-2-interacting protein) expression, which was independent of transcription of mRNA and required protein synthesis. In addition, Molt-4 cells treated with As2O3 exhibited the down-regulation of Bax protein expression, suggesting that Bax may be involved in accumulating of Beclin-1 and triggering autophagic cell death in As2O3-treated leukemia cells. These results may lead to a better understanding of the mechanism of action of As2O3, and provide a suggestion that As2O3 may be of therapeutic value for the treatment of patients with human T-lymphocytic leukemia and myelodysplastic syndrome.

Apoptosis Regulatory Proteins↗

[Inhibition effect of topotecan on human myelodysplastic syndrome cells in vitro and in vivo].

OBJECTIVE: To investigate the effect of topotecan (TPT) on human myelodysplastic syndrome (MDS) cells in vitro and in vivo. METHODS: Cell growth was measured by a MTT assay. The percentage of cells undergoing apoptosis was determined by flow cytometry after staining with annexin V-FITC and propidium iodide. The morphology of apoptotic cells was observed by transmission electron microscopy (TEM). Furthermore, the antitumor effect on MDS cells in xenotransplanted severe combined immunodeficiency (SCID) mice was evaluated by tumor volume and survival. Western blot was used for determining the expression of topoisomerase I (Top1) protein. RESULT: The growth of Mutz-1 cells was suppressed by TPT treatment in a dose-dependent manner. The 50% inhibition in Mutz-1 cell growth (IC(50)) of TPT for 72 h was 272 ng/L. The percentage of apoptotic cells observed in the Mutz-1 cells after exposure to TPT (160 ng/L) in 48 h and 72 h was (54.16 +/-4.29)% and (72.97+/-6.12)%, respectively. TEM showed the characteristics of apoptosis in Mutz-1 cells treated with TPT. The xenotransplanted SCID mice treated with TPT showed inhibited tumor growth compared with control group. TPT treatment resulted in a longer survival as compared with the control group (P<0.001) and with the As2O3-treated group (P<0.001). The cells exposed to TPT exhibited a time-dependent decrease of Top1 protein expression. CONCLUSION: TPT can inhibit Mutz-1 cell growth and induce apoptosis in vitro.The downregulation of Top1 may be involved in the apoptosis induced by TPT. TPT has a significant antitumor effect in vivo.

Animals↗

[WT1 gene expression in myelodysplastic syndrome and its clinical implication].

OBJECTIVE: To investigate the expression of WT1 gene in myelodysplastic syndrome (MDS) and to explore its clinical implications. METHODS: Expression of WT1 mRNA was detected in 53 patients with myelodysplastic syndrome and 10 healthy subjects by reverse transcriptase polymerase chain reaction (RT-PCR). RESULT: WT1 gene was expressed in all MDS patients. The positive rate and expression level in MDS patients were higher than those in healthy subjects. The positive rates of WT1 expression in MDS-RAEB and MDS-RAEB-t groups were higher than those in MDS-RA and MDS-RAS groups. The expression level was gradually increased from MDS-RA and MDS-RAS groups to MDS-RAEB and MDS-RAEB-t groups. CONCLUSION: The expression of WT1 gene might be associated with the development of MDS, and it can be used for risk assessment and monitor of disease progression and therapeutic effects in MDS patients.

Adolescent↗

[Construction of expression vector of hTERT/hIL-18 fusion gene in eukaryotic cells and its function].

OBJECTIVE: To construct expression vector of hTERT-hIL-18 fusion gene in eukaryotic cells and to study its biological function. METHODS: hIL-18 gene was amplified by RT-PCR, then T-A cloned and inserted into PCDNA3.1(+)/hTERT vector. The sequence of fusion gene was examined by enzyme incision and DNA sequencing. The vector with fusion gene was transformed into 3T3 cells by the method of lipofecting, and proved by Western blot. The secretion gamma-interferon was measured with ELISA and cell apoptosis was detected with flow cytometry. RESULT: Expression vector PCDNA3.1(+) of hTERT/hIL-18 fusion gene was constructed successfully. The correct sequence was proved by enzyme incision and sequencing and there was a correct open reading frame. Fusion protein of hTERT/hIL-18 was effectively expressed in eukaryotic cells and was proved by Western blot and immunofluorescence stain. The fusion protein stimulated KG-1 cells to secrete gamma-interferon and had anti-apoptosis effect. CONCLUSION: Fusion protein hTERT-hIL-18 is highly effectively expressed in eukaryotic cells and is biologically active.

Base Sequence↗

[The value of dynamic color duplex scanning in the diagnosis of vascular erectile dysfunction].

OBJECTIVE: To evaluate deep penile arterial flow after an intracavernosal injection with prostaglandin E1 in patients with erectile dysfunction (ED). METHODS: 527 patients with ED were evaluated using Color Doppler Ultrasonography. Diagnostic tests were undertaken after an intracavernosal injection with 20 microg prostaglandin El. The peak systolic velocity (PSV), end diastolic velocity (EDV) and resistive index (RI) were analysed. RESULTS: There were 112 patients (26.99%) with nonvasculogenic ED, 207 patients (49.88%) with arteriogenic ED, 144 patients (34.70%)with venogenic ED, 64 patients (15.42%)with mixed ED. CONCLUSION: The Color Doppler Ultrasonography technique allows accurate location and evaluation of deep penile arteries. Vascular pathology may be differentiated after an intracavernosal injection with a vasomotor agent. Recognising the pathological pattern assists in choosing the best method of treatment.

Adult↗